Merck
CN

UHPLC Analysis of Intact Infliximab on BIOshell A400 Protein C4

UHPLC Analysis of Intact Infliximab on BIOshell A400 Protein C4 application for UHPLC

材料

分析色谱柱

产品编号
说明
价格

BIOshell A400 Protein C4, 3.4 μm HPLC Column

3.4 μm particle size, L × I.D. 10 cm × 2.1 mm

标准

产品编号
说明
价格

SILuMAb英利昔单抗稳定同位素标记单克隆抗体

recombinant, expressed in CHO cells

流动相组分

产品编号
说明
价格

正丁醇

analytical standard

乙腈

suitable for HPLC, gradient grade, ≥99.9%

三氟乙酸

≥99%, for protein sequencing

CONDITIONS

column

BIOshell A400 Protein C4; 10 cm x 2.1 mm I.D., 3.4 μm particles (66825-U)

mobile phase

[A] 70:25:5 water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA); [B] 50:45:5 water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA)

gradient

0% B to 100% B in 15 min

flow rate

0.2 mL/min

pressure

680 psi (46 Bar)

column temp.

75 °C

detector

UV, 215 nm

injection

5 μL

sample

Infliximab, 100 μg/mL, water (0.05% TFA)

说明

分析说明

Infliximab (brand name Remicade) is an immunosuppressive biologic drug used to treat rheumatoid arthritis, psoriatic arthritis, Crohn′s disease, and many other diseases by blocking TNF alpha which prevents an autoimmune reaction. It has a molecular weight of ~150 kDa. The BIOshell A400 Protein C4 UHPLC column yielded an efficient peak for this protein in less than five minutes.

法律信息

null